Aytu BioPharma Inc. (NASDAQ:AYTU) traded with a subtraction of -$0.01 to close at $0.18 on Friday, a downside of -3.78 percent. An average of 835,655 shares of common stock have been traded in the last five days. There was a fall of -$0.0306 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 985,864 shares traded, while the 50-day average volume stands at 995,376.
AYTU stock has decreased by -7.35% in the last month. The company shares reached their 1-month lowest point of $0.1780 on 12/30/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.15 and a high of $1.59 in 52 weeks. It has reached a new high 2 times so far this year and lost -86.28% or -$1.1709 in price. In spite of this, the price is down -88.79% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Aytu BioPharma Inc. (AYTU) stock’s beta is -0.14. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.12, the price-to-book (PB) ratio at 0.17.
The quick ratio of Aytu BioPharma Inc. for the three months ended September 29 was 0.80, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.25 and a total debt to equity ratio of 0.42 for the quarter ending September 29. Its gross profit as reported stood at $52.28 million compared to revenue of $96.67 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Aytu BioPharma Inc.’s return on assets was -50.10%.
For the three-month period that ended September 29, Aytu BioPharma Inc. had $13.56 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$2.88 million in the quarter, while revenues of -$17.7 million were shrunk -867.01%. The analyst consensus anticipated Aytu BioPharma Inc.’s latest quarter earnings to come in at -$0.18 per share, but it turned out to be -$0.06, a 66.70% surprise. For the quarter, EBITDA amounted to $0.82 million. Shareholders own equity worth $62.43 million.
From a technical analysis perspective, let’s take a brief look at Aytu BioPharma Inc. (AYTU) price momentum. RSI 9-day as of the close on 29 December was 33.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 79.80%.
As of today, AYTU’s price is $0.1859 -14.59% or -$0.0306 from its 5-day moving average. AYTU is currently trading -15.84% lower than its 20-day SMA and -36.35% lower than its 100-day SMA. However, the stock’s current price level is +11.80% above the SMA50 and -83.57% below the SMA200.
The stochastic %K and %D were 8.95% and 10.17%, respectively, and the average true range (ATR) was 0.0178. With the 14-day stochastic at 1.67% and the average true range at 0.0182, the RSI (14) stands at 39.75%. The stock has reached -0.0135 on the 9-day MACD Oscillator while the 14-day reading was at -0.0189.
Cantor Fitzgerald launched coverage on Aytu BioPharma Inc. (NASDAQ: AYTU) in its analyst report released on March 30, 2021. The firm assigned the stock an Overweight rating. The consensus rating for Aytu BioPharma Inc. (AYTU) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AYTU, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is AYTU’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $6.00, with a median target of $5.50. Taking a look at these predictions, the average price target given by analysts for Aytu BioPharma Inc. (AYTU) stock is $5.50.